Heparan sulphates for use in repair and/or regeneration of skin
AssigneeAgency for Science, Technology and Research
InventorsSimon Cool, Victor Nurcombe
Life of this patent
Estimating the term…
Abstract
Affinity purification of fibroblast growth factor 2-binding heparan sulphate from porcine mucosa (HS8) is disclosed. Also disclosed is the use of HS8 in repair and regeneration of the skin for treating wounds, burns, ulcers and other skin injuries.
Claims16
Heparan sulphate HS8 for use in a therapeutic method of repair and/or regeneration of skin.
Use of Heparan sulphate HS8 in the manufacture of a medicament for use in a therapeutic method of repair and/or regeneration of skin.
A method of healing a skin wound comprising contacting the skin wound with an effective amount of a pharmaceutical composition comprising heparan sulphate HS8.
A method of treating a subject having a skin wound, the method comprising administration of a therapeutically effective amount of heparan sulphate HS8 to the subject leading to repair and/or regeneration of skin at the wound.
A method of skin grafting, skin reconstruction, or skin plastic surgery comprising contacting the skin at or adjacent the region of grafting, reconstruction or plastic surgery with an effective amount of a pharmaceutical composition comprising HS8.
HS8 for use in a therapeutic method of repair and/or regeneration of skin, the use or the method of any one of the preceding claim wherein the HS8, medicament or pharmaceutical composition is formulated for topical or transdermal administration.
HS8 for use in a therapeutic method of repair and/or regeneration of skin, the use or the method of any one of the preceding claim wherein the HS8, medicament or pharmaceutical composition is formulated as a gel, spray, paste, ointment, cream, lotion, salve, oil, aqueous solution, suspension, dispersion, patch, adhesive plaster, bandage, dressing, depot, or reservoir.
HS8 for use in a therapeutic method of repair and/or regeneration of skin, the use or the method of any one of the preceding claims wherein the method further comprises administration of a growth factor, preferably FGF2, and/or mesenchymal stem cells.
HS8 for use in a therapeutic method of repair and/or regeneration of skin, the use or the method of any one of the preceding claims wherein the HS8, medicament or pharmaceutical composition is formulated as a combined preparation with a growth factor, preferably FGF2, and/or with mesenchymal stem cells.
HS8 for use in a therapeutic method of repair and/or regeneration of skin, the use or the method of any one of the preceding claims wherein the heparan sulphate HS8 is provided in isolated or substantially purified form.
HS8 for use in a therapeutic method of repair and/or regeneration of skin, the use or the method of any one of the preceding claims wherein the heparan sulphate HS8 is capable of binding a peptide or polypeptide having, or consisting of, the amino acid sequence YCKNGGF (SEQ ID NO:2) or GHFKDPKRLYCKNGGF (SEQ ID NO:1).
HS8 for use in a therapeutic method of repair and/or regeneration of skin, the use or the method of any one of the preceding claims wherein following digestion with heparin lyases I, II and III and then subjecting the resulting disaccharide fragments to capillary electrophoresis analysis the heparan sulphate HS8 has a disaccharide composition comprising:
- Disaccharide
- Normalised weight percentage
- ΔUA,2S-GlcNS,6S
- 12.7 ± 3.0
- ΔUA,2S-GlcNS
- 7.2 ± 2.0
- ΔUA-GlcNS,6S
- 15.5 ± 3.0
- ΔUA,2S-GlcNAc,6S
- 6.5 ± 2.0
- ΔUA-GlcNS
- 15.7 ± 3.0
- ΔUA,2S-GlcNAc
- 1.0 ± 0.5
- ΔUA-GlcNAc,6S
- 8.9 ± 3.0
- ΔUA-GlcNAc
- 32.5 ± 3.0
HS8 for use in a therapeutic method of repair and/or regeneration of skin, the use or the method of any one of the preceding claims wherein the HS8 is obtained by a method comprising:
- (i) providing a solid support having polypeptide molecules adhered to the support, wherein the polypeptide comprises a heparin-binding domain having the amino acid sequence YCKNGGF;
- (ii) contacting the polypeptide molecules with a mixture comprising glycosaminoglycans such that polypeptide-glycosaminoglycan complexes are allowed to form;
- (iii) partitioning polypeptide-glycosaminoglycan complexes from the remainder of the mixture;
- (iv) dissociating glycosaminoglycans from the polypeptide-glycosaminoglycan complexes;
- (v) collecting the dissociated glycosaminoglycans.
Dependencies are inferred from the claim text.